Journal of Infection and Public Health
Volume 2, Issue 2 , Pages 62-73 , 2009

Antibiotic therapeutic options for infections caused by drug-resistant Gram-positive cocci

  • K. Banwan

      Affiliations

    • Division of Microbiology, Department of Laboratory Medicine, Amiri Hospital, Safat, Kuwait
    • ,
  • A.C. Senok

      Affiliations

    • Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
    • ,
  • V.O. Rotimi

      Affiliations

    • Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait
    • Corresponding Author InformationCorresponding author. Tel.: +965 498 6509; fax: +965 533 2719.

Received 9 February 2009 ,Revised 6 April 2009 ,Accepted 6 April 2009.

References 

  1. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect. 2005;11(3):22–28
  2. Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol. 2007;
  3. Kern WV. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int J Clin Pract. 2006;60:370–378
  4. Jerala R. Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin Investig Drugs. 2007;16:1159–1169
  5. Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006;7:1381–1397
  6. Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991;35:1710–1716
  7. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 2000;46:523–526
  8. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318–1323
  9. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2006;12(1):24–32
  10. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 2002;46:31–33
  11. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799–2807
  12. Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact. 2004;150:137–147
  13. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001;45:1919–1922
  14. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother. 2004;53:669–674
  15. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother. 2003;47:1968–1971
  16. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother. 2003;47:337–341
  17. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  18. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  19. Kurt GN, Barry AL, Francis PT. Daptomycin versus Ciprofloxacin in the treatment of complicated urinary tract infection due to Gram-positive bacteria. Infect Dis Clin Pract. 2004;12:322–327
  20. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149–2152
  21. Guay DR. Daptomycin: the first approved lipopeptide antimicrobial. Consult Pharm. 2004;19:614–628
  22. Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm. 2006;63:1235–1243
  23. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006;26:1099–1110
  24. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol. 2001;1:464–469
  25. Pankey GA, Tigecycline . J Antimicrob Chemother. 2005;56:470–480
  26. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28:1079–1106
  27. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother. 2004;53:592–599
  28. Bergeron J, Ammirati M, Danley D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996;40:2226–2228
  29. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100mg dose. J Antimicrob Chemother. 2006;58:1221–1229
  30. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin Ther. 2005;27:12–22
  31. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004). Diagn Microbiol Infect Dis. 2005;52:195–201
  32. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis. 2005;52:187–193
  33. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis. 2005;52:203–208
  34. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin–aztreonam. Clin Infect Dis. 2005;41(5):S341–353
  35. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41(5):S354–367
  36. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg. 2005;3:35–47
  37. Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem–cilastatin. Surg Infect (Larchmt). 2007;8:159–172
  38. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63:52–61
  39. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–142
  40. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997;41:2127–2131
  41. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 1998;42:3251–3255
  42. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42:1129–1140
  43. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775–2780
  44. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother. 2000;46:931–940
  45. Johnson AP, Henwood C, Mushtaq S, James D, Warner M, Livermore DM. Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. J Hosp Infect. 2003;54:179–187
  46. Al Sweih N, Mokaddas E, Jamal W, Phillips OA, Rotimi VO. In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait. J Chemother. 2005;17:607–613
  47. Phillips OA, Rotimi VO, Jamal WY, Shahin M, Verghese TL. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria. J Chemother. 2003;15:113–117
  48. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother. 2007;41:296–308
  49. Viale P, Pagani L, Cristini F, et al. Linezolid for the treatment of central nervous system infections in neurosurgical patients. Scand J Infect Dis. 2002;34:456–459
  50. Plouffe JF. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid. Clin Infect Dis. 2000;31(4):S144–149
  51. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000;44:3408–3413
  52. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2005;26:442–448
  53. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260–2266
  54. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481–1490
  55. Rubinstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid . (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402–412
  56. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47:1824–1831
  57. Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS. Linezolid-associated toxic optic neuropathy. Neurology. 2006;66:595–598
  58. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA. 2001;285:1291
  59. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis. 2005;5:209–218
  60. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother. 1997;39(Suppl. A):7–13
  61. Johnston NJ, Mukhtar TA, Wright GD. Streptogramin antibiotics: mode of action and resistance. Curr Drug Targets. 2002;3:335–344
  62. Bearden DT. Clinical pharmacokinetics of quinupristin/dalfopristin. Clin Pharmacokinet. 2004;43:239–252
  63. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin–dalfopristin (RP 59500 Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 1998;31:437–451
  64. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis. 1999;33:101–112
  65. Blondeau JM, Sanche SE. Quinupristin/dalfopristin. Expert Opin Pharmacother. 2002;3:1341–1364
  66. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999;58:1061–1097
  67. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin Synercid Skin and Skin Structure Infection Group.. J Antimicrob Chemother. 1999;44:263–273
  68. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium Synercid Emergency-Use Study Group. J Antimicrob Chemother. 1999;44:251–261
  69. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin Nosocomial Pneumonia Group. Am J Respir Crit Care Med. 2000;161:753–762
  70. Moellering RC. Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother. 1999;44(Suppl. A):25–30
  71. Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007;61:853–863
  72. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis. 2004;48:137–143
  73. Leimkuhler C, Chen L, Barrett D, et al. Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics. J Am Chem Soc. 2005;127:3250–3251
  74. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:940–945
  75. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374–380
  76. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298–1303
  77. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407–1415

PII: S1876-0341(09)00032-X

doi: 10.1016/j.jiph.2009.04.003

Journal of Infection and Public Health
Volume 2, Issue 2 , Pages 62-73 , 2009

Article Tools